---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-012546"
form_type: "8-K"
ticker: "OGN"
cik: "0001821825"
company_name: "Organon & Co."
filed_at: "2025-02-13T23:59:59+00:00"
generated_at: "2026-05-26T22:23:13.115481+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Organon FY2024 revenue $6.4B (+2%); guides FY2025 revenue $6.125-6.325B

## Summary
- Full year 2024 revenue $6,401M (+2% as-reported, +3% constant currency); diluted EPS $3.33; non-GAAP adjusted diluted EPS $4.11.
- Q4 revenue $1,592M flat YoY; net income $109M vs $546M (down 80%) due to prior-year one-time gain; adjusted net income $235M (+4%).
- FY2025 guidance: revenue $6,125M-$6,325M (incl. ~$200M FX headwind); Adjusted EBITDA margin 31-32% (FY2024: 30.6%).
- Biosimilars Q4 revenue down 18% on tender timing and U.S. pricing pressure; Women's Health flat as Nexplanon +12% offset NuvaRing decline.
- Established Brands +2% driven by Emgality (Lilly license) and Vtama (Dermavant acquisition closed Oct 2024), partly offset by Atozet LOE.

## SEC filing metadata
- accession: 0001104659-25-012546
- form_type: 8-K
- ticker: OGN
- cik: 0001821825
- company_name: Organon & Co.
- filed_at: 2025-02-13T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1821825/000110465925012546/0001104659-25-012546-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1821825/000110465925012546/tm256470d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-012546
- JSON: https://secwatch.observer/filing/0001104659-25-012546.json
- Plain text: https://secwatch.observer/filing/0001104659-25-012546.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.